This inventor holds 8 USPTO granted patents and 2 published patent applications and 2 EPO patents. Top assignees: Endogena Therapeutics, Inc., Hoffmann-La Roche Inc.. Active years: 2005-2026.
Company Filing History:
Years Active: 2005-2026
Title: Matthias Steger: Innovator in Retinal Disease Treatment
Introduction
Matthias Steger is a prominent inventor based in Zurich, Switzerland. He has made significant contributions to the field of retinal disease treatment, holding a total of 8 patents. His work focuses on developing compounds that stimulate the production of retinal precursor cells, which are crucial for treating neuroretinal diseases.
Latest Patents
Among his latest patents, Steger has developed N-(4-(oxazol-5-yl)phenyl) chromane-3-carboxamide derivatives and related compounds. These compounds serve as stimulators for the production of retinal precursor cells, addressing conditions that lead to photoreceptor loss or outer-retina degeneration. The patented methods involve administering specific compounds or their pharmaceutically acceptable salts, which include a variety of chemical residues that enhance their therapeutic efficacy.
Career Highlights
Throughout his career, Matthias Steger has worked with notable companies such as Endogena Therapeutics, Inc. and Hoffmann-La Roche Inc. His innovative approaches have positioned him as a key figure in the development of treatments for retinal diseases.
Collaborations
Steger has collaborated with esteemed colleagues, including Alex Mueller and Mauro Marigo. These partnerships have furthered his research and contributed to the advancement of therapeutic solutions in the field.
Conclusion
Matthias Steger's work exemplifies the impact of innovation in medical science, particularly in the treatment of retinal diseases. His patents and collaborations highlight his commitment to improving patient outcomes through groundbreaking research.